EUVIMEDEUVIMED entdecken
Open Access

Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3

Bozhi Ye iD, Wante Lin, Yucheng Jiang, Zhaozheng Zheng, Yanhong Jin, Diyun Xu, Yingjie Liao, Zhihan Jia, Jiaji Chen, Gaojun Wu iD, Peiren Shan iD, Guang Liang iD

Science Advances · 2025

DOI: 10.1126/sciadv.adu8422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Bozhi Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital, Wenzhou Medical University, Wenz…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Cardiomegaly, Myocytes, Cardiac. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying previously unknown targets for pathological cardiac hypertrophy and understanding its mechanisms are crucial. Here, we observed that the deubiquitinating enzyme YOD1 was moderately elevated in human hypertrophic myocardium and mouse models. Cardiomyocyte-specific knockout of YOD1 reduced Ang II– and TAC-induced cardiac hypertrophy. Subsequently, we used multiple proteomic analyses to identify and confirm STAT3 as a substrate protein for YOD1. Mechanistically, our findings revealed that the C155 site of YOD1 removes K48-linked ubiquitin chains from K97 on STAT3, stabilizing STAT3 levels and enhancing its nuclear translocation in cardiomyocytes under Ang II stimulation. Notably, inhibiting STAT3 reversed the antihypertrophic effects of YOD1 deficiency in Ang II–challenged mice. In addition, pharmacological inhibition of YOD1 mitigated Ang II–induced pathological ventricular remodeling in mice. This study clarifies the role of YOD1 and introduces a previously unidentified YOD1-STAT3 axis in regulating pathological cardiac hypertrophy, providing valuable insights for drug development targeting this condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorCardiomegalyMyocytes, CardiacAnimalsMiceHumansUbiquitinationMice, KnockoutDisease Models, AnimalMaleAngiotensin II

Substanzen

STAT3 Transcription FactorStat3 protein, mouseAngiotensin II

Autor:innen und Institutionen

  • Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.

ORCID-Profile: Bozhi Ye, Gaojun Wu, Peiren Shan, Guang Liang

Zitieren

APA

Ye, B., Lin, W., Jiang, Y., Zheng, Z., Jin, Y., Xu, D., Liao, Y., Jia, Z., Chen, J., Wu, G., Shan, P., & Liang, G. (2025). Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3. Science Advances. https://doi.org/10.1126/sciadv.adu8422

Vancouver

Ye B, Lin W, Jiang Y, Zheng Z, Jin Y, Xu D, et al. Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3. Science Advances. 2025. doi:10.1126/sciadv.adu8422

BibTeX
@article{Ye2025,
  author = {Ye, Bozhi and Lin, Wante and Jiang, Yucheng and Zheng, Zhaozheng and Jin, Yanhong and Xu, Diyun and Liao, Yingjie and Jia, Zhihan and Chen, Jiaji and Wu, Gaojun and Shan, Peiren and Liang, Guang},
  title = {Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adu8422}
}
Kostenlos starten →